Raveron® versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Bircan, K.; ÖZEN, HASAN; Ergen, A.; Başar, I.; Özgür, S.; Ilker, Y.; Karaaĝaoĝlu, AHMET; Remzi, D.

doi:10.1007/bf02549794

Raveron® versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Copy For Citation

Bircan K., ÖZEN H., Ergen A., Başar I., Özgür S., Ilker Y., ...More

International Urology and Nephrology, vol.22, no.4, pp.345-348, 1990 (Scopus)

Publication Type: Article / Article
Volume: 22 Issue: 4
Publication Date: 1990
Doi Number: 10.1007/bf02549794
Journal Name: International Urology and Nephrology
Journal Indexes: Scopus
Page Numbers: pp.345-348
Lokman Hekim University Affiliated: No

Abstract

Thirty patients with BPH were randomized into two groups to receive Raveron® and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron® and placebo. © 1990 Akadémiai Kiadó.